Skip to content

Development of Oligo-PROTACs That Target C/EBPα.

Aug 2026 · ACS Chemical Biology · 0 citations · 37 references
Medicine

TL;DR

It is demonstrated that these O'PROTACs successfully localize to the nucleus and achieve dose-dependent degradation of C/EBPα, with the most potent candidates exhibiting sub-micromolar DC50 via lipofection delivery.

Abstract

CCAAT/enhancer-binding protein alpha (C/EBPα) is a critical lineage-defining transcription factor and tumor suppressor. Despite its clinical significance in conditions like acute myeloid leukemia and hepatocellular carcinoma (HCC), C/EBPα has remained undruggable due to its intrinsically disordered regions and lack of small-molecule binding pockets. In this study, we describe the development of a novel Oligonucleotide-based PROteolysis-TArgeting Chimera (Oligo-PROTAC or O'PROTAC) strategy designed to achieve targeted degradation of endogenous C/EBPα. We designed and synthesized a 10-nucleotide double-stranded DNA decoy derived from a C/EBPα-binding motif and conjugated it via variable linkers to the E3 ligase ligands pomalidomide or VH032. A total of six candidates were synthesized and evaluated in 3T3-J2 and Huh7 cell lines. We demonstrate that these O'PROTACs successfully localize to the nucleus and achieve dose-dependent degradation of C/EBPα, with the most potent candidates exhibiting sub-micromolar DC50 via lipofection delivery. Notably, this degradation occurred without inducing significant cytotoxicity. We observe a transcriptional shift consistent with loss of C/EBPα, including downregulation of cooperative factors involved in liver lineage specification and their downstream target genes. This work establishes O'PROTACs as a viable modality for targeting C/EBPα, offering a novel strategy for mechanistic investigation and future therapeutic targeting.

View source

Similar papers

Review Open access Oct 2026

Targeted Degradation of the c-Myc Oncoprotein: Molecular Mechanisms, Technological Platforms, and Therapeutic Perspectives in Oncology

Background/Objectives: The c-Myc oncoprotein is a master regulator of cell cycle progression, cellular metabolism, and ribosome biogenesis, and its dysregulation occurs in more than 70% of human malignancies. Its intrinsically disordered structure and absence of deep hydrophobic binding pockets have historically limite...

T. Lupanova, Georgii P. Georgiev, A. S. Sobolev · 0 citations
Sep 2026

Abstract B005: Synergistic targeting of EP300/CBP and EYA co-activators collapses the rhabdomyosarcoma core regulatory circuit

Rhabdomyosarcoma (RMS) is a high-risk pediatric sarcoma that resembles developing skeletal muscle. Transcriptional dysregulation drives RMS pathogenesis in tumors carrying chimeric transcription factors (“fusion-positive (FP)”), and those without (“fusion-negative” (FN)). Here, we develop a novel approach against RMS...

Brian J. Abraham, Annika L. Gustafson, S. Nance et al. · 0 citations
Sep 2026

Abstract B009: DNA-proximal MYB phosphorylation is required for oncogenic transcription in acute myeloid leukemia

DNA-proximal phosphorylation of MYB is identified as a critical regulatory mechanism required for MYB oncogenesis through cooperative organization of transcription factors and nominated MYB N-terminal phosphorylation and its upstream kinases as candidate therapeutic targets for MYB-dependent leukemia.

Shu-Yuan Cheng, Katarzyna Kulej, Masahiro Uni et al. · 0 citations
Review Open access Oct 2026

Research Progress on Targeted Degradation of Transcription Factors Based on PROTAC Technology

For transcription factors (TFs), biological importance has not always translated into pharmacological tractability. These proteins coordinate gene expression programs involved in proliferation, differentiation, immune homeostasis, and development, yet many disease-relevant TFs lack the compact binding pockets that make...

Meng-Lin Han · 0 citations
Review Open access Oct 2026

Harnessing the ubiquitin-proteasome system: advances and challenges of PROTACs in breast cancer

Overall, PROTACs can become a novel therapeutic approach in the treatment of breast cancer, and a knowledge gap exists that limits the understanding of E3 ligases, constraining their tissue specificity and metabolism.

Hannah Lalengzuali Fanai, B. Babu, K. Rajagopal et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.